Obesity has emerged as one of the most pressing public health challenges globally, affecting over 650 million adults, ...

Pennsylvania's Medicaid spending per enrollee on Wegovy, Zepbound and other anti-obesity drugs was third-highest in the ...

Biomea also drilled down into subgroups of patients with mild age-related diabetes and severe insulin-deficient diabetes, ...

Based on these initial results and the upcoming 52-week readout in the second half 2025, Biomea plans to engage with the FDA to discuss the data. This meeting will provide an opportunity to align with ...

The annual meeting of the American Society of Hematology was held from Dec. 7 to 10 in San Diego and attracted participants ...

A research team from the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has identified a mechanistic link between high blood glucose levels and weakened immunity against viral ...

These drugs have been in wide medical use for quite some time—Victoza was first approved for the treatment of type 2 diabetes in 2010, for example—but they have become ... demands that Novo Nordisk ...

While Spruce Biosciences Inc.’s tildacerfont missed its phase II primary endpoint in classic congenital adrenal hyperplasia (CAH) last March, the U.S. FDA has now approved Crenessity (crinecerfont) ...

Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT’s Therapeutic Vector Evolution platform to invent ...

An estimated 80 million people above the age of 18 years have diabetes in India, in addition to 25 million 2 that are pre-diabetic.

UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...

As the incoming administration prepares to enact sweeping changes to health policy, including Robert F. Kennedy Jr.’s ...